The global fill-finish pharmaceutical contract manufacturing market was valued at USD 18.0 billion in 2024 and is projected to reach USD 29.1 billion by 2030, expanding at a CAGR of 8.3% from 2025 to 2030. The market is expected to increase from USD 21.1 billion in 2026. North America represented the largest regional market in 2024, accounting for 34.9% of global revenue.

A major factor shaping the industry is the growing tendency of pharmaceutical and biopharmaceutical companies to outsource fill-finish activities to specialized contract manufacturing organizations (CMOs). Outsourcing enables drug developers to focus resources on discovery and development while reducing infrastructure requirements, operational complexity, and investment risks.

Key Market Trends & Insights

Outsourcing Expands Across Pharmaceutical Manufacturing

Pharmaceutical companies are increasingly relying on specialized CMOs for fill-finish operations. By transferring activities such as sterile filling and final drug-product processing to external providers, manufacturers can concentrate on core capabilities while gaining access to specialized production infrastructure and technical expertise.

This model can also help companies manage operational risks and control capital expenditure, particularly as drug development becomes more complex and biologics account for a growing share of pharmaceutical pipelines.

Injectable Drug Demand Strengthens Fill-finish Requirements

The expanding use of injectable medicines is creating additional demand for efficient and reliable fill-finish capacity. Chronic diseases, including diabetes and cardiovascular conditions, continue to contribute to pharmaceutical demand, increasing the need for injectable drug manufacturing capabilities.

Healthcare investment is also supporting pharmaceutical market development in emerging economies. The supplied market data highlights increasing healthcare expenditure in Asia Pacific, particularly India and China, while China's healthcare spending reached 6.6% of GDP. Mexico also presents expanding pharmaceutical demand, with approximately 70.9% of its 128 million population covered by health services.

Biologics Increase the Need for Specialized Manufacturing

The continued development of biologics, including monoclonal antibodies and vaccines, is creating demand for specialized fill-finish capabilities capable of handling complex formulations, high-potency products, and large-volume production.

Biopharmaceutical companies accounted for the largest end-use share in 2024 at 55.3%, while large molecules represented 67.3% of the market by molecule type. These figures highlight the importance of biologics-oriented manufacturing capabilities within the contract fill-finish landscape.

Download a free sample report or claim your copy of this full market intelligence report

Technology and Regulatory Developments Improve Manufacturing Efficiency

Technological advancements are improving fill-finish manufacturing efficiency while supporting quality and regulatory compliance. Modern processes are increasingly designed to accommodate complex biologics and demanding pharmaceutical production requirements.

Regulatory developments are also influencing market dynamics. Authorities such as China's NMPA and Argentina's ANMAT have been accelerating approval processes, supporting pharmaceutical manufacturing activity and creating opportunities for specialized service providers.

Emerging Markets Attract Local Manufacturing Investment

Healthcare infrastructure investments and pharmaceutical localization initiatives are creating new opportunities for CMOs and CDMOs in emerging markets. Saudi Arabia and India are notable examples where public and private investments are supporting domestic pharmaceutical and biopharmaceutical manufacturing capacity.

In June 2023, Saudi Arabia's Public Investment Fund launched Lifera, a CDMO focused on developing local biopharmaceutical manufacturing capabilities. The initiative is aligned with Saudi Arabia's Vision 2030 and aims to strengthen domestic production and the supply of essential medicines.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Market Structure at a Glance

• Product: Vials represented the leading product category, accounting for 53.4% of revenue in 2024.
• Molecule: Large molecules held the largest share at 67.3% in 2024.
• End Use: Biopharmaceutical companies accounted for 55.3% of revenue.
• Region: North America led globally with 34.9% of revenue in 2024.
• North America: The U.S. represented 88.3% of the regional market in 2024.
• Growth: Asia Pacific is identified as the fastest-growing regional market.

Market Size & Forecast

Competitive Landscape

The fill-finish pharmaceutical contract manufacturing industry includes global pharmaceutical service providers and specialized contract manufacturing organizations with capabilities spanning sterile manufacturing, biologics, injectable products, and pharmaceutical development.

Key companies identified in the market include:

• Thermo Fisher Scientific Inc.
• Sartorius AG
• Boehringer Ingelheim International GmbH
• Catalent, Inc. (acquired by Novo Holdings A/S)
• Societal CDMO (Recro Pharma, Inc.)
• Baxter
• Eurofins Scientific
• Symbiosis Pharmaceutical Services Ltd.
• MabPlex International Co. Ltd.
• Recipharm AB

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.